February 28, 2023

Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer

Read More >
March 31, 2022

Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital

Read More >
August 5, 2020

ARC Therapeutics Launches to Develop Novel CDK Inhibitors for the Treatment of Advanced and Resistant Cancers

Read More >